Needham & Company LLC restated their buy rating on shares of Heron Therapeutics (NASDAQ:HRTX - Free Report) in a research note released on Friday morning,Benzinga reports. Needham & Company LLC currently has a $4.00 price objective on the biotechnology company's stock.
Separately, StockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, January 29th.
Get Our Latest Analysis on Heron Therapeutics
Heron Therapeutics Stock Performance
HRTX stock traded up $0.31 during midday trading on Friday, reaching $2.55. The stock had a trading volume of 2,692,158 shares, compared to its average volume of 1,805,542. The firm has a fifty day simple moving average of $1.70 and a two-hundred day simple moving average of $1.71. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The stock has a market cap of $387.84 million, a PE ratio of -14.17 and a beta of 1.60.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to analysts' expectations of $37.37 million. On average, sell-side analysts predict that Heron Therapeutics will post -0.13 EPS for the current fiscal year.
Institutional Investors Weigh In On Heron Therapeutics
Hedge funds have recently bought and sold shares of the stock. Nicolet Advisory Services LLC purchased a new stake in Heron Therapeutics during the fourth quarter worth $25,000. Argent Advisors Inc. purchased a new position in Heron Therapeutics during the fourth quarter worth approximately $31,000. Focus Partners Wealth acquired a new stake in Heron Therapeutics in the fourth quarter valued at approximately $31,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Heron Therapeutics in the third quarter valued at approximately $39,000. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Heron Therapeutics in the third quarter valued at approximately $45,000. Hedge funds and other institutional investors own 80.01% of the company's stock.
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Articles
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
